Koeberl, Dwight DCase, Laura EDesai, AnkitSmith, Edward CWalters, CristaHan, Sang-OhThurberg, Beth LYoung, Sarah PBali, DeekshaKishnani, Priya S2023-02-012023-02-012020-021096-71921096-7206https://hdl.handle.net/10161/26520This 24-week, Phase I/II, double-blind, randomized, placebo-controlled study investigated the safety and efficacy of extended-release albuterol in late-onset Pompe disease stably treated with enzyme replacement therapy at the standard dose for 4.9 (1.0-9.4) years and with no contraindications to intake of albuterol. Twelve of 13 participants completed the study. No serious adverse events were related to albuterol, and transient minor drug-related adverse events included muscle spasms and tremors. For the albuterol group, forced vital capacity in the supine position increased by 10% (p < .005), and forced expiratory volume in one second increased by 8% (p < .05); the six-minute walk test increased 25 m (p < .05; excluding one participant unable to complete muscle function testing); the Gross Motor Function Measure increased by 8% (p < .005) with the greatest increases in the Standing (18%; p < .05) and Walking, Running, and Jumping (11%; p < .005) subtests. No significant improvements would be expected in patients with late-onset Pompe disease who were stably treated with enzyme replacement therapy. The placebo group demonstrated no significant increases in performance on any measure. These data support a potential benefit of extended-release albuterol as adjunctive therapy in carefully selected patients with late-onset Pompe disease based on ability to take albuterol on enzyme replacement therapy (NCT01885936).Muscle, SkeletalHumansGlycogen Storage Disease Type IIAlbuterolVital CapacityForced Expiratory VolumeTreatment OutcomeDouble-Blind MethodAdultMiddle AgedFemaleMaleEnzyme Replacement TherapyLate Onset DisordersWalk TestJournal article2023-02-01